09:48 AM EST - Medexus Pharmaceuticals : Provided a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conferences. Medexus has seen an encouraging market response to GRAFAPEX™ in the weeks since the February 24 commercial launch of the product. Several procedures using commercially available GRAFAPEX™ have already occurred, which is consistent with company expectations regarding initial institutional uptake and patient-level demand for the product. Medexus Pharmaceuticals
shares T.MDP are trading down $0.14 at $2.01.
